Literature DB >> 19487337

From real-world events to psychosis: the emerging neuropharmacology of delusions.

Paul D Morrison1, R M Murray.   

Abstract

The earliest stages of delusion are characterized by an overabundance of meaningful coincidences impinging on the sufferer's existing worldview. Successive events are seen by him as pointing to, and then confirming, a fundamentally new reality that takes him over and engulfs his everyday life. Research over the last 4 decades has revealed the importance of dopamine (DA), D2 receptors, and the basal ganglia in psychotic thinking. Recent work has implicated the aberrant reward learning initiated by the excess release of striatal DA in the attribution of excessive importance or "salience" to insignificant stimuli and events. But our knowledge of what is happening beyond D2 receptors has remained scant. The gap is especially apparent at the cellular and microcircuit levels, encompassing the plastic changes, which are believed to be essential for new learning, and whose processes may go awry in major mental illness. Now new pharmacological findings are advancing our understanding of information processing and learning within the striatum. DA has an important role in setting the strength of individual striatal connections, but it does not act in isolation. Two other modulator systems are critical, the endocannabinoids and adenosine. Thus, at medium spiny neurons belonging to the indirect pathway, D2 stimulation evokes endocannabinoid-mediated depression of cortical inputs. Adenosine acting at A2A receptors elicits the opposite effect. Remarkably, drugs that target the endocannabinoid and purinergic systems also have pro- or antipsychotic properties. Here, we discuss how the 3 modulators regulate learning within the striatum and how their dysfunction may lead to delusional thinking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487337      PMCID: PMC2696381          DOI: 10.1093/schbul/sbp049

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  61 in total

Review 1.  The basal ganglia: a vertebrate solution to the selection problem?

Authors:  P Redgrave; T J Prescott; K Gurney
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 2.  Changes in behavior-related neuronal activity in the striatum during learning.

Authors:  Wolfram Schultz; Léon Tremblay; Jeffrey R Hollerman
Journal:  Trends Neurosci       Date:  2003-06       Impact factor: 13.837

3.  Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum.

Authors:  Madoka Narushima; Motokazu Uchigashima; Kouichi Hashimoto; Masahiko Watanabe; Masanobu Kano
Journal:  Eur J Neurosci       Date:  2006-10-17       Impact factor: 3.386

4.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

5.  Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions.

Authors:  S Akhondzadeh; E Shasavand; H Jamilian; O Shabestari; A Kamalipour
Journal:  J Clin Pharm Ther       Date:  2000-04       Impact factor: 2.512

6.  Postsynaptic endocannabinoid release is critical to long-term depression in the striatum.

Authors:  G L Gerdeman; J Ronesi; D M Lovinger
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

7.  Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum.

Authors:  B Szabo; L Dörner; C Pfreundtner; W Nörenberg; K Starke
Journal:  Neuroscience       Date:  1998-07       Impact factor: 3.590

Review 8.  Dopamine-mediated regulation of corticostriatal synaptic plasticity.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Massimiliano Di Filippo
Journal:  Trends Neurosci       Date:  2007-03-23       Impact factor: 13.837

9.  Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity.

Authors:  Louise Adermark; Giuseppe Talani; David M Lovinger
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

10.  The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.

Authors:  P D Morrison; V Zois; D A McKeown; T D Lee; D W Holt; J F Powell; S Kapur; R M Murray
Journal:  Psychol Med       Date:  2009-04-01       Impact factor: 7.723

View more
  11 in total

Review 1.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

Review 2.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

3.  A classification of sociomedical health indicators: perspectives for health administrators and health planners.

Authors:  A E Siegmann
Journal:  Int J Health Serv       Date:  1976       Impact factor: 1.663

4.  The epidemiology of schizophrenia: replacing dogma with knowledge.

Authors:  Simona A Stilo; Robin M Murray
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

5.  Ventral striatum gray matter density reduction in patients with schizophrenia and psychotic emotional dysregulation.

Authors:  Katharina Stegmayer; Helge Horn; Andrea Federspiel; Nadja Razavi; Tobias Bracht; Karin Laimböck; Werner Strik; Thomas Dierks; Roland Wiest; Thomas J Müller; Sebastian Walther
Journal:  Neuroimage Clin       Date:  2013-12-27       Impact factor: 4.881

Review 6.  Gene × Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models.

Authors:  Paula Moran; Jennifer Stokes; Julia Marr; Gavin Bock; Lieve Desbonnet; John Waddington; Colm O'Tuathaigh
Journal:  Neural Plast       Date:  2016-09-20       Impact factor: 3.599

Review 7.  Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings.

Authors:  Albert Batalla; Sagnik Bhattacharyya; Murat Yücel; Paolo Fusar-Poli; Jose Alexandre Crippa; Santiago Nogué; Marta Torrens; Jesús Pujol; Magí Farré; Rocio Martin-Santos
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

8.  ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.

Authors:  M Mizuno; H Sotoyama; H Namba; M Shibuya; T Eda; R Wang; T Okubo; K Nagata; Y Iwakura; H Nawa
Journal:  Transl Psychiatry       Date:  2013-04-30       Impact factor: 6.222

9.  Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study.

Authors:  Rebecca Kuepper; Jenny Ceccarini; Johan Lataster; Jim van Os; Marinus van Kroonenburgh; Joop M A van Gerven; Machteld Marcelis; Koen Van Laere; Cécile Henquet
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

10.  A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.

Authors:  H Bentsen; K Osnes; H Refsum; D K Solberg; T Bøhmer
Journal:  Transl Psychiatry       Date:  2013-12-17       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.